MedTrace Logo

Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation

NCT05084586 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-03-28

No results posted yet for this study

Summary

In this study, the local and systemic side effects, tumor recurrens and progression rates of single or continuous epirubicin instillation during the early postoperative period were investigated in low and intermediate risk non-muscle-invasive bladder cancer.

Conditions

  • Bladder Cancer
  • Epirubicin Adverse Reaction
  • Superficial Bladder Cancer
  • Tumor Recurrence

Interventions

DRUG

Intravesical Solution

After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 150 ml saline was continuously instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.

DRUG

Intravesical Solution

After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 50 ml saline was instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.

Sponsors & Collaborators

  • Ankara Training and Research Hospital

    lead OTHER

Principal Investigators

  • Ali Kaan Yildiz · Ankara Training and Resarch Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2023-10-05
Completion
2023-11-05

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05084586 on ClinicalTrials.gov